Citadel Advisors
PTVE

Citadel Advisors’s Pactiv Evergreen Inc. Common stock PTVE Stock Holding History

Citadel Advisors’s Portfolio PTVE Stock Details PTVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,800
Closed -$303K – 15795
2025
Q1 		$303K Sell
16,800
-1,100
-6% -$19.6K ﹤0.01% 9564
2024
Q4 		$313K Buy
17,900
+3,400
+23% +$46K ﹤0.01% 9569
2024
Q3 		$167K Buy
14,500
+4,600
+46% +$52.8K ﹤0.01% 10420
2024
Q2 		$112K Buy
9,900
+1,000
+11% +$13.3K ﹤0.01% 10753
2024
Q1 		$127K Buy
8,900
+7,300
+456% +$103K ﹤0.01% 11021
2023
Q4 		$21.9K Buy
1,600
+1,400
+700% +$14.7K ﹤0.01% 12544
2023
Q3 		$1.63K Sell
200
-1,100
-85% -$8.99K ﹤0.01% 13833
2023
Q2 		$9.84K Sell
1,300
-600
-32% -$4.58K ﹤0.01% 13237
2023
Q1 		$15.2K Sell
1,900
-1,600
-46% -$16.5K ﹤0.01% 13264
2022
Q4 		$39.8K Buy
+3,500
New +$38.2K ﹤0.01% 12426

Citadel Advisors's PTVE Position: Q2 2025 in Review

Citadel Advisors sold out of Pactiv Evergreen Inc. Common stock (PTVE) in Q2 2025, closing a stake of 132,475 shares — an estimated $2.39M sold.

Citadel Advisors first reported a position in PTVE in Q3 2020 and held it in 17 quarters. The position peaked at $2.41M in Q2 2023. 0 funds tracked by Wall St. Rank hold PTVE as of Q2 2025.

  • Citadel Advisors reported no remaining Pactiv Evergreen Inc. Common stock position as of Q2 2025 after selling out during the quarter.
  • Citadel Advisors sold 132,475 Pactiv Evergreen Inc. Common stock shares in Q2 2025, an estimated $2.39M.
  • Citadel Advisors first reported a position in Pactiv Evergreen Inc. Common stock in Q3 2020 and held it in 17 quarters.
  • Citadel Advisors's Pactiv Evergreen Inc. Common stock position peaked at $2.41M in Q2 2023.
  • 0 funds tracked by Wall St. Rank held Pactiv Evergreen Inc. Common stock as of Q2 2025.

Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.